세계의 항정신병약 시장 규모 조사 및 예측 : 질환별, 약효군별, 유통채널별, 지역별 분석(2023-2030년)

Global Antipsychotic Drugs Market is valued approximately at USD 15.47 billion in 2022 and is anticipated to grow with a growth rate of more than 6% over the forecast period 2023-2030. Antipsychotic drugs are medications used to manage symptoms of psychotic disorders like schizophrenia and bipolar disorder. They work by altering neurotransmitter activity in the brain, particularly dopamine and serotonin. There are two main types: first-generation (typical) and second-generation (atypical) antipsychotics. First-generation drugs such as chlorpromazine primarily block dopamine receptors, while second-generation medications like risperidone affect both dopamine and serotonin receptors. Second-generation antipsychotics are preferred due to their reduced risk of movement disorders. These medications are prescribed based on the severity of symptoms and individual response, with close monitoring to manage side effects. The surge in mental disorder prevalence, the expanding geriatric demographic, shifting preference towards atypical antipsychotics, and rising awareness programs focusing on mental health collectively fuel market expansion for antipsychotic drugs across the globe. Additionally, the growing emphasis on education and advocacy aimed at reducing stigma and promoting human rights further propels growth within the global antipsychotic drugs market.

In addition, the rise in prevalence of mental health disorders to propel market expansion globally.

This surge in the global patient population is anticipated to fuel market growth significantly. For instance, a 2022 article published by the World Health Organization (WHO) projected that mental disorders could impose an estimated USD 6.0 trillion burden on the global economy by 2030. Such statistics are anticipated to stimulate the demand for these therapeutics as awareness regarding the severity of mental illnesses continues to increase. According to WHO estimates from 2022, approximately 970.0 million individuals globally, or about 1 in every eight people, were living with mental disorders such as anxiety and depression in 2019. However, in recent years, there has been a rise in the prevalence of schizophrenia and bipolar disorder. Consequently, several pharmaceutical companies have intensified their research and development efforts in this domain, leading to the introduction of new products in the forecast period. These factors are poised to drive substantial global market growth in the coming years. Moreover, the rise in the adoption of Long-Acting Injectables (LAIs), as well as the growing R&D initiatives for the development of novel antipsychotic drugs presents various lucrative opportunities over the forecasting years. However, the several side effects associated with antipsychotic drugs and the rise in cost of mental health programs are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Antipsychotic Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the high prevalence of psychiatric disorders and the presence of leading biopharmaceutical companies. According to the 2022 report from the National Alliance on Mental Illness (NAMI), the annual prevalence of bipolar disorder in the U.S. is 2.8%, affecting an estimated 7 million individuals. Additionally, the region's strong adoption of technologically advanced antipsychotics contributes significantly to its market position. Moreover, robust awareness campaigns highlighting the severity of mental illnesses are expected to further propel market growth in North America throughout the forecast period. Whereas, Asia Pacific is expected to grow the fastest over the forecast years. The rising awareness campaigns about psychiatric disorders and the rising prevalence of mental health conditions are significantly propelling the market demand across the region.

Major market players included in this report are:

• H. Lundbeck A/S (Denmark)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Belgium)
• Eli Lilly and Company (U.S.)
• ALLERGAN (AbbVie, Inc.) (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Dr. Reddy's Laboratories Ltd. (India)
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
• Alkermes plc (Ireland)
• Bristol-Myers Squibb Company (U.S.)

Recent Developments in the Market:

• In February 2023, Lupin introduced a generic antipsychotic medication in the United States, available in strengths of 20, 40, 60, 80, and 120 mg. This generic variant mirrors Sunovion Pharmaceuticals Inc.'s Latuda tablets.
• In March 2022, AbbVie initiated a co-development and licensing partnership with Gedeon Richter Plc. This collaboration aims to research, develop, and commercialize dopamine receptor modulators intended for the potential treatment of neuropsychiatric diseases.
• In February 2022, Alkermes plc reported favorable outcomes from ENLIGHTEN-Early, a phase 3b study examining the impact of LYBALVI (olanzapine and samidorphan) in comparison to olanzapine on body weight in young adult patients aged 16 to 39, with diagnoses of schizophrenia, schizophreniform disorder, or bipolar I disorder (mean age: 26 years).
• In January 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S secured approval from the U.S. FDA for the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in patients aged 13 to 17 years.

Global Antipsychotic Drugs Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Disease, Drug, Therapeutic Class, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease:

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Others

By Drug:

• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others

By Therapeutic Class:

• First Generation
• Second Generation
• Third Generation

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Antipsychotic Drugs Market, by region, 2020-2030 (USD Billion)
  • 1.2.2.Antipsychotic Drugs Market, by Disease, 2020-2030 (USD Billion)
  • 1.2.3.Antipsychotic Drugs Market, by Drug, 2020-2030 (USD Billion)
  • 1.2.4.Antipsychotic Drugs Market, by Therapeutic Class, 2020-2030 (USD Billion)
  • 1.2.5.Antipsychotic Drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Antipsychotic Drugs Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Antipsychotic Drugs Market Dynamics

• 3.1.Antipsychotic Drugs Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Increasing number of awareness programs focusing on mental health
    • 3.1.1.2.Rising prevalence of mental health disorders
  • 3.1.2.Market Challenges
    • 3.1.2.1.Side effects associated with antipsychotic drugs
    • 3.1.2.2.Rise in cost of mental health programs
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Rise in the adoption of Long-Acting Injectables (LAIs)
    • 3.1.3.2.Growing R&D initiatives for development of novel antipsychotic drugs

Chapter 4.Global Antipsychotic Drugs Market: Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economic
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Antipsychotic Drugs Market, by Disease

• 5.1.Market Snapshot
• 5.2.Global Antipsychotic Drugs Market by Disease, Performance - Potential Analysis
• 5.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Disease 2020-2030 (USD Billion)
• 5.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 5.4.1.Schizophrenia
  • 5.4.2.Bipolar Disorder
  • 5.4.3.Unipolar Depression
  • 5.4.4.Dementia
  • 5.4.5.Others

Chapter 6.Global Antipsychotic Drugs Market, by Drug

• 6.1.Market Snapshot
• 6.2.Global Antipsychotic Drugs Market by Drug, Performance - Potential Analysis
• 6.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Drug 2020-2030 (USD Billion)
• 6.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 6.4.1.Risperidone
  • 6.4.2.Quetiapine
  • 6.4.3.Olanzapine
  • 6.4.4.Aripiprazole
  • 6.4.5.Brexpiprazole
  • 6.4.6.Paliperidone Palmitate
  • 6.4.7.Others

Chapter 7.Global Antipsychotic Drugs Market, by Therapeutic Class

• 7.1.Market Snapshot
• 7.2.Global Antipsychotic Drugs Market by Therapeutic Class, Performance - Potential Analysis
• 7.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Therapeutic Class 2020-2030 (USD Billion)
• 7.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 7.4.1.First Generation
  • 7.4.2.Second Generation
  • 7.4.3.Third Generation

Chapter 8.Antipsychotic Drugs Market, by Distribution Channel

• 8.1.Market Snapshot
• 8.2.Global Antipsychotic Drugs Market by Distribution Channel, Performance - Potential Analysis
• 8.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 8.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 8.4.1.Hospital Pharmacies
  • 8.4.2.Drug Stores & Retail Pharmacies
  • 8.4.3.Online Pharmacies

Chapter 9.Global Antipsychotic Drugs Market, Regional Analysis

• 9.1.Top Leading Countries
• 9.2.Top Emerging Countries
• 9.3.Antipsychotic Drugs Market, Regional Market Snapshot
• 9.4.North America Antipsychotic Drugs Market
  • 9.4.1.U.S. Antipsychotic Drugs Market
    • 9.4.1.1.Disease breakdown estimates & forecasts, 2020-2030
    • 9.4.1.2.Drug breakdown estimates & forecasts, 2020-2030
    • 9.4.1.3.Therapeutic Class breakdown estimates & forecasts, 2020-2030
    • 9.4.1.4.Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 9.4.2.Canada Antipsychotic Drugs Market
• 9.5.Europe Antipsychotic Drugs Market Snapshot
  • 9.5.1.U.K. Antipsychotic Drugs Market
  • 9.5.2.Germany Antipsychotic Drugs Market
  • 9.5.3.France Antipsychotic Drugs Market
  • 9.5.4.Spain Antipsychotic Drugs Market
  • 9.5.5.Italy Antipsychotic Drugs Market
  • 9.5.6.Rest of Europe Antipsychotic Drugs Market
• 9.6.Asia-Pacific Antipsychotic Drugs Market Snapshot
  • 9.6.1.China Antipsychotic Drugs Market
  • 9.6.2.India Antipsychotic Drugs Market
  • 9.6.3.Japan Antipsychotic Drugs Market
  • 9.6.4.Australia Antipsychotic Drugs Market
  • 9.6.5.South Korea Antipsychotic Drugs Market
  • 9.6.6.Rest of Asia Pacific Antipsychotic Drugs Market
• 9.7.Latin America Antipsychotic Drugs Market Snapshot
  • 9.7.1.Brazil Antipsychotic Drugs Market
  • 9.7.2.Mexico Antipsychotic Drugs Market
• 9.8.Middle East & Africa Antipsychotic Drugs Market
  • 9.8.1.Saudi Arabia Antipsychotic Drugs Market
  • 9.8.2.South Africa Antipsychotic Drugs Market
  • 9.8.3.Rest of Middle East & Africa Antipsychotic Drugs Market

Chapter 10.Competitive Intelligence

• 10.1.Key Company SWOT Analysis
• 10.2.Top Market Strategies
• 10.3.Company Profiles
  • 10.3.1.H. Lundbeck A/S (Denmark)
    • 10.3.1.1.Key Information
    • 10.3.1.2.Overview
    • 10.3.1.3.Financial (Subject to Data Availability)
    • 10.3.1.4.Product Summary
    • 10.3.1.5.Recent Developments
  • 10.3.2.Otsuka Pharmaceutical Co., Ltd. (Japan)
  • 10.3.3.Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Belgium)
  • 10.3.4.Eli Lilly and Company (U.S.)
  • 10.3.5.ALLERGAN (AbbVie, Inc.) (U.S.)
  • 10.3.6.Teva Pharmaceutical Industries Ltd. (Israel)
  • 10.3.7.Dr. Reddy's Laboratories Ltd. (India)
  • 10.3.8.Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • 10.3.9.Alkermes plc (Ireland)
  • 10.3.10.Bristol-Myers Squibb Company (U.S.)

Chapter 11.Research Process

• 11.1.Research Process
  • 11.1.1.Data Mining
  • 11.1.2.Analysis
  • 11.1.3.Market Estimation
  • 11.1.4.Validation
  • 11.1.5.Publishing
• 11.2.Research Attributes
• 11.3.Research Assumption